Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label study of two 1% pimecrolimus ointment formulations in adults with atopic dermatitis
2004-003798-94Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pimecrolimus in atopic dermatitis (AD) (2 arms), sponsored by Novartis. Primary endpoints: Pharmacokinetic endpoints and Safety and tolerability assessments. Started Nov 2004; status: completed.
02
Drugs
pimecrolimus
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2004-003798-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003798-94.